NOTICE TO ALL DOCTORS, NURSES AND PHARMACISTS

THERAPEUTIC ALTERNATIVES TO NEVIRAPINE SUSPENSION FOR USE IN NEONATES FOR PREVENTION OF MOTHER TO CHILD TRANSMISSION

The contracted suppliers for nevirapine suspension are experiencing supply problems. Suppliers will only be able to resume supply as follows:

- 100 mL – end August 2014
- 240 mL – January 2015

The recommended therapeutic alternative is:

- Zidovudine, oral

<table>
<thead>
<tr>
<th>Infant age</th>
<th>Daily dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth to 6 weeks</td>
<td></td>
</tr>
<tr>
<td>Birthweight 2000-2499 g</td>
<td>10 mg twice daily</td>
</tr>
<tr>
<td>Birthweight ≥ 2500 g</td>
<td>15 mg twice daily</td>
</tr>
</tbody>
</table>

The other acceptable alternative is:

- Lamivudine, oral, 2 mg/kg/dose 12 hourly

The duration of treatment is the same as set out in the nevirapine-based PMTCT guidelines. See the Standard Treatment Guidelines and Essential Medicines List for Paediatrics (2013 edition, page 9.6)

Please ensure that the contents of this circular is brought to the attention of all relevant prescribers.

MR G STEEL
CLUSTER MANAGER: SECTORWIDE PROCUREMENT
DATE: 19-08-2014